EBITDA: Income before interest, taxes, depreciation and amortization.
Lyell Immunopharma, Inc. (LYEL) had EBITDA of $-45.17M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$0.01M |
|
$-42.68M |
|
-- |
|
$0.01M |
|
$47.15M |
|
$-47.14M |
|
$4.46M |
|
$-42.68M |
|
$-42.68M |
|
$-42.68M |
|
$-42.68M |
|
$-42.68M |
|
$-42.68M |
|
$-47.14M |
|
|
EBITDA |
$-45.17M |
14.79M |
|
14.79M |
|
$-2.89 |
|
$-2.89 |
|
| Balance Sheet Financials | |
$282.21M |
|
$39.12M |
|
$103.24M |
|
$385.45M |
|
$36.90M |
|
-- |
|
$49.63M |
|
$86.53M |
|
$298.92M |
|
$298.92M |
|
$298.92M |
|
14.83M |
|
| Cash Flow Statement Financials | |
$-89.20M |
|
$82.11M |
|
$0.18M |
|
$107.29M |
|
$100.39M |
|
$-6.90M |
|
$11.03M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.65 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-589249.90% |
|
-589249.90% |
|
-- |
|
-533549.90% |
|
-533549.90% |
|
$-89.61M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-14.28% |
|
-14.28% |
|
-11.07% |
|
-14.28% |
|
$20.16 |
|
$-6.06 |
|
$-6.03 |
|